HER2/neu expression in relation to clinicopathologic features of breast cancer patients

Annals of the New York Academy of Sciences

Volumn 1089, Issue , 2006, Pages 159-167

  Traina, Adele ^a,c   Agostara, Biagio ^b   Marasà, Lorenzo ^a   Calabrò, Maurizio ^a   Zarcone, Maurizio ^a   Carruba, Giuseppe ^a  

^a ARNAS Civico   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Experimental Oncology Unit   (Italy)

Author keywords

Breast cancer; HER2 neu; Overall survival analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; ADULT; AGED; ARTICLE; BREAST TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 33847774749     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1386.029     Document Type: Conference Paper

References (21)

1. STERN, D.F., P.A. HEFFERNAN & R.A. WEINBERG. 1986. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell Biol. 6: 1729-1740.
2. HYNES, N.E. & D.F. STERN. 1994. The biology of erbB-2/neu/HER2/NEU and its role in cancer. Bioch. Biophys. Acta 1198: 165-184.
3. AKIYAMA, T., C. SUDO, H. OGAWARA, et al. 1986. The product of human c-erbB-2 gene: a 185 Kilodalton glycoprotein with tyrosineKinase activity. Science 232: 1644-1646.
4. BARGMANN, C.I., M.C. HUNG & R.A. WEINBERG. 1986. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230.
5. COUSSENS, L., T.L. YANG-FENG, Y.-C. LIAO, et al. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139.
6. SCHECHTER, A.L., D.F. STERN, L. VAIDYANATHAN, et al. 1984. The neu oncogene: an erbB-related gene encoding a 185,000-Mr tumour antigen. Nature 213: 513-516.
7. RIESE, D.J. & D.F. STERN. 1998. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41-48.
8. MAGUIRE, H.C. & M.I. GREENE. 1989. The neu (c-erbB-2) oncogene. Semin. Oncol. 16: 148-155
9. VAN DER GEER, P., T. HUNTER & R.A. LINDBERG. 1994. Receptor protein tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell. Biol. 10: 251-337.
10. PINKAS-KRAMARSKI, R., R. EILAM, I. ALROY, et al. 1997. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. Oncogene 15: 2803-2815.
11. KLAPPER, L.N., S. GLATHE, N. VAISMAN, et al. 1999. The ErbB-2/HER2/NEU oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA 96: 4995-5000.
12. PINKAS-KRAMARSKI, R., M. SHELLY, B.C. GUARINO, et al. 1998. erbB Tyrosine kinases and two neuregulin families constitute a ligand receptor network. Mol. Cell. Biol. 18: 6090-6101.
13. ALROY, I. & Y. YARDEN. 1997. The erbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interaction. FEBS Lett. 410: 83-86.
14. TZAHAR, E., G. LEVKOWITZ, D. KARUNAGARAN, et al. 1996. A hierarchical network of interreceptor interactions determines sal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16: 5276-5287.
15. SLAMON, D.J., W. GODOLPHIN, L.A. JONES, et al. 1989. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
16. SLAMON, D.J., G.M. CLARK, S.G. WONG, et al. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182.
17. LÜFTNER, D., A. JUNG, P. SCHIMID, et al. 2003. Upregulation of HER2/neu by ovarian ablation: results of a randomized trial comparing leuproein to CMF as adjuvant therapy in node-positive breast cancer patient. Breast Cancer Res. Treat. 80: 245-255.
18. GOLDHIRSCH, A., J.H. GLICK, W. R.D. GELBER,, et al. 2005. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann. Oncol. 16: 1569-1583.
19. REED, W. E. HANNISDAL, P.J. BOEHLER, et al. 1989. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 88:804-813.
20. BASELGA, J., L. GIANNI, C. GEYER, et al. 2004. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin. Oncol. 31(5 Suppl. 10): 51-57. Review.
21. CASTAGNETTA, L.M. et al. 2002. Ligand binding and cytochemical analysis of estrogen and progesterone receptors in relation to follow-up in patients with breast cancer. Ann. N. Y. Acad. Sci. 963: 98-103.